Read the circled quote.
They intend to submit potency data linking prior batches to the batch that will be used in the coming adult trial - this means they need the outcomes of that trial.
If that trial is a flop, and they're intending to compare those two batches, then it doesn't validate anything. And on the flip side, if the trial is successful it does.
So they need the outcomes of the adult trial. What is the point otherwise.
They have said it themselves in the release. And it's what I've been saying all along that would happen - yet again.
I can't hold your hand any more than I am now. If you don't understand, you never will.
Ann: Mesoblast Partners with BMT CTN on Adult SR-aGVHD Trial, page-32
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.10 |
Change
0.000(0.00%) |
Mkt cap ! $1.250B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.08 | $5.380M | 4.893M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 69437 | $1.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.10 | 19999 | 1 |
View Market Depth
| Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |